REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA
Clinical trials for REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests a two-step treatment for adults with large B-cell lymphoma that returned or didn't respond to prior therapy. First, patients receive tafasitamab (an antibody that targets cancer cells) plus lenalidomide (a drug that helps the immune system fight cancer). Then, th…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 17, 2026 09:11 UTC
-
Engineered immune cells take on HIV-Linked lymphoma in new trial
Disease control Recruiting nowThis phase 1 trial is testing a CAR-T cell therapy (axicabtagene ciloleucel) in 20 adults with HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to recognize and attack cancer c…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug duo shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether combining two targeted drugs—loncastuximab tesirine and mosunetuzumab—can shrink or eliminate tumors in people with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. About 36 adults will receive the drug combination, and…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:01 UTC